pharmaphorum3d
Trial finds benefit for GLP-1 agonist in Parkinson’s
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...
GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, ...
Indiatimes5d
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
When a GLP-1 drug similar to Ozempic helped slow Parkinson's symptoms A recent New England Journal of Medicine study tested lixisenatide, a GLP-1 drug, as a potential treatment for early-stage ...
The Lancet6d
First phase 3 trial of GLP-1 receptor agonist for neurodegeneration
The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...